$PBIO Mr. Bradley, CEO of RedShiftBio, stated: “
Post# of 27046
(Total Views: 198)
Posted On: 04/27/2020 11:24:05 AM
$PBIO Mr. Bradley, CEO of RedShiftBio, stated: “…accelerated stability testing in formulations development could potentially be reduced to weeks, if not days. Consequently, the PCT-enhanced MMS platform could potentially be used to achieve new drug approvals in significantly less time than required today.”
(0)
(0)Scroll down for more posts ▼